Preclinical efficacy and safety assessment of nano-oxaliplatin oral formulation prepared by novel Fat Employing Supercritical Nano System, the FESNS®.
It is expected that oral cancer drug will provide ease of administration with decreased unwanted events to the patients. The purpose of this study is to prepare oral formulation of nano-oxaliplatin and examine the anticancer efficacy and safety. Nano-oxaliplatin was prepared utilizing our proprietary technology, the Fat Employing Supercritical Nano System (FESNS(®)). It showed regular nanoparticles with a mean diameter of around 212 nm. When nano-oxaliplatin was orally administered in rats, the relative bioavailability of nano-oxaliplatin oral formulations was about 25-31% compared to the Eloxatin(®) administered intravenously (i.v.). For antitumor activity in xenograft model, nano-oxaliplatin oral formulation (20 mg/kg, once daily) presented superior inhibition of tumor growth against Eloxatin(®) (5 mg/kg, i.v. once a week). In single-dose toxicity, dead animals were observed at or above 1000 mg/kg (LD(50): 888.38 mg/kg for male; 725.43 mg/kg for female rats). In repeated dose toxicity, there were hematological changes observed in rats, which is a common finding in the class of cancer drugs. It was thought that the expected dose level that has cytotoxic effect without death would be 30 mg/kg in rats, which is double the dose level of Eloxatin(®). Nano-oxaliplatin oral formulation changed the pharmacokinetic behavior of crude oxaliplatin, thus increasing oral bioavailability as well as its anticancer activity. In addition, single and repeated dose toxicity studies indicated that oral nano-oxaliplatin is superior in toxicity at the pharmacologically active doses compared to Eloxatin(®) in rats. Nano-oxaliplatin oral formulation has potential as a novel anticancer therapy.